quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:15:00·794d
PRRelease
Advaxis, Inc. logo
Immunome Inc. logo

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

ADXS· Advaxis, Inc.IMNM· Immunome Inc.
Health Care
Original source

Companies

  • ADXS
    Advaxis, Inc.
    Health Care
  • IMNM
    Immunome Inc.
    Health Care

Recent analyst ratings

  • Feb 12IMNMUpdateH.C. Wainwright$40.00
  • Dec 1IMNMUpdateTruist$36.00
  • Sep 22IMNMUpdateGoldman$26.00
  • Sep 5IMNMUpdateCraig Hallum$26.00
  • Apr 2IMNMUpdateLake Street$23.00
  • Nov 8IMNMUpdateStephens$30.00

Related

  • PR3d
    Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
  • INSIDER20d
    SEC Form 4 filed by Higgins Jack
  • INSIDER20d
    SEC Form 4 filed by Rosett Max
  • PR21d
    Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • INSIDER22d
    SEC Form 4 filed by Higgins Jack
  • INSIDER24d
    SEC Form 4 filed by Siegall Clay B
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.
  • INSIDER31d
    SEC Form 4 filed by Wagenheim Philip
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022